Palvannanathan Ganesan, MD
Pulmonary Disease · Omaha, NENPI 1891716718
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 391 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AstraZeneca at 24.5% of the total.
Across 391 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Harmony Biosciences LLC$1K
- Actelion Pharmaceuticals US, Inc.$543
- Jazz Pharmaceuticals Inc.$511
- GSK$462
- Boehringer Ingelheim$411
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,952100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 74 | $1,945 |
| Harmony Biosciences LLC | 68 | $1,235 |
| Actelion Pharmaceuticals US, Inc. | 23 | $543 |
| Jazz Pharmaceuticals Inc. | 23 | $511 |
| GSK | 33 | $462 |
| Boehringer Ingelheim | 26 | $411 |
| Mylan Specialty L.p. | 16 | $260 |
| Amgen | 10 | $255 |
| United Therapeutics Corporation | 12 | $226 |
| Grifols USA, LLC | 8 | $213 |
| Insmed, Inc. | 15 | $205 |
| Sanofi | 6 | $201 |
| Regeneron Healthcare Solutions, Inc. | 10 | $161 |
| Avadel CNS Pharmaceuticals, LLC | 7 | $160 |
| Electromed, Inc. | 11 | $158 |
| Johnson & Johnson | 7 | $132 |
| Axsome Therapeutics, Inc. | 5 | $113 |
| Mallinckrodt Hospital Products Inc. | 3 | $85 |
| Baxter Healthcare | 4 | $82 |
| Bayer | 3 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $74 |
| Astellas Pharma US Inc | 3 | $69 |
| Viatris Specialty LLC | 3 | $61 |
| Merck | 2 | $50 |
| Sunovion Pharmaceuticals Inc. | 5 | $39 |
| Pulmonx Corporation | 1 | $38 |
| Vifor Pharma, Inc. | 2 | $34 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| AbbVie | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Philips North America LLC | 1 | $18 |
| Pfizer | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,952 in reported general payments places this provider in the 75th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 22 | $282,131 |
| UptraviSelexipag | 12 | $180,066 |
| NucalaMepolizumab | 13 | $47,213 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $46,576 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $10,522 |
| DuleraMometasone/Formoterol | 25 | $10,096 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $10,037 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,934 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $9,925 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,640 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,797 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $3,802 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $3,115 |
| Sildenafil Citrate | 11 | $2,615 |
| Roflumilast | 28 | $1,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $543 | $462,19734 claims |
| GSKNucala, Trelegy Ellipta, Anoro Ellipta, Breo Ellipta | $462 | $111,951118 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $1,945 | $19,97149 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $411 | $15,72225 claims |
| MerckDulera | $50 | $10,09625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Omaha
- Stephen RennardOmaha$50K
- Douglas MooreOmaha$40K
- Adam WellsOmaha$26K
- Zachary DepewOmaha$26K
- Michael SanleyOmaha$17K
- Adam HighleyOmaha$15K
- Carolina LandeenOmaha$14K
- Patrick MeyersOmaha$12K
- John DickinsonOmaha$8K
- Lee MorrowOmaha$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.